ClinVar Miner

Submissions for variant NM_000151.4(G6PC1):c.1039C>T (p.Gln347Ter)

gnomAD frequency: 0.00026  dbSNP: rs80356487
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 18
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000199372 SCV000230856 pathogenic not provided 2015-04-07 criteria provided, single submitter clinical testing
GeneDx RCV000199372 SCV000251525 pathogenic not provided 2022-05-12 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect on enzyme function (Lei et al., 1994); Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 11 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); This variant is associated with the following publications: (PMID: 24385852, 10874313, 8182131, 29970488, 28397058, 34093448, 31589614, 33101979, 24077912, 27535533, 34258141)
Invitae RCV000012780 SCV000776256 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2024-01-29 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln347*) in the G6PC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 11 amino acid(s) of the G6PC protein. This variant is present in population databases (rs80356487, gnomAD 0.04%). This premature translational stop signal has been observed in individuals with glycogen storage disease type 1A (PMID: 7573034, 8182131, 8733042, 10070617, 11949931, 28397058). ClinVar contains an entry for this variant (Variation ID: 12000). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects G6PC function (PMID: 8182131). For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics, Fulgent Genetics RCV000012780 SCV000894123 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2018-10-31 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000012780 SCV000919368 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2017-09-25 criteria provided, single submitter clinical testing Variant summary: The G6PC c.1039C>T (p.Gln347X) variant results in a premature termination codon, predicted to cause a truncated or absent G6PC protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant was found in 56/276802 control chromosomes at a frequency of 0.0002023, which does not exceed the estimated maximal expected allele frequency of a pathogenic G6PC variant (0.0017321). Multiple publications have cited the variant in affected compound heterozygote and homozygote individuals that had little to none glucose-6-phosphatase activity. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Baylor Genetics RCV000012780 SCV001163792 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2022-11-15 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV000012780 SCV001194080 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2019-11-12 criteria provided, single submitter clinical testing NM_000151.3(G6PC):c.1039C>T(Q347*) is classified as pathogenic in the context of glycogen storage disease type Ia. Sources cited for classification include the following: PMID 8733042, 10738525, 19815695, 10874313, 24385852, 18449899, 7573034, 10070617 and 8182131. Classification of NM_000151.3(G6PC):c.1039C>T(Q347*) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.
CeGaT Center for Human Genetics Tuebingen RCV000199372 SCV001334652 pathogenic not provided 2023-02-01 criteria provided, single submitter clinical testing G6PC1: PM3:Strong, PM2, PVS1:Moderate, PP1, PS3:Supporting
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000199372 SCV001762112 pathogenic not provided 2021-06-17 criteria provided, single submitter clinical testing
Genetic Diagnostics Department, Viafet Genomics Laboratory RCV000012780 SCV001976440 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2021-08-23 criteria provided, single submitter clinical testing As part of Carrier Screening testing performed at Viafet Genomics Laboratory, this variant was identified in a heterozygous state in a patient who is not affected with this condition. This variant is present in exon 5/5 in a position that is conserved across 1/2 transcripts of this gene. A loss-of-function variant is reported as disease-causing in HGMD and ClinVar after this position. This variant has been identified in a homozygous and compound heterozygous state in patients affected with Glycogen Storage Disease Ia (PMIDs: 8182131, 28397058, and 33101979). In addition, studies on biopsies from patients' liver cells have shown that this variant causes undetectable G6Pase Phosphohydrolase activity compared to the wildtype (PMIDs: 8182131 and 8733042).
Ambry Genetics RCV002512992 SCV003737475 pathogenic Inborn genetic diseases 2021-07-17 criteria provided, single submitter clinical testing The c.1039C>T (p.Q347*) alteration, located in exon 5 (coding exon 5) of the G6PC gene, consists of a C to T substitution at nucleotide position 1039. This changes the amino acid from a glutamine (Q) to a stop codon at amino acid position 347. This alteration occurs at the 3' terminus of the G6PC gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 11 amino acids of the protein. However, premature stop codons are typically deleterious in nature. This mutation has been reported in the homozygous and compound heterozygous state in individuals with G6PC-related glycogen storage disease type I (Lei, 1994; Peeks, 2017). G6Pase was not detectable when this mutation was expressed in COS1 cells; it was also not detectable in liver biopsy samples of affected individuals homozygous or compound heterozygous for p.Q347* (Lei, 1994). Based on the available evidence, this alteration is classified as pathogenic.
Revvity Omics, Revvity Omics RCV000012780 SCV003820021 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2022-11-28 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000199372 SCV003853549 pathogenic not provided 2021-05-06 criteria provided, single submitter clinical testing PVS1, PS4_moderate, PM2, PP4
Preventiongenetics, part of Exact Sciences RCV003398491 SCV004120656 pathogenic G6PC1-related condition 2023-09-12 criteria provided, single submitter clinical testing The G6PC1 c.1039C>T variant is predicted to result in premature protein termination (p.Gln347*). This variant has been well documented as causative for glycogen storage disease type Ia (e.g., Lei et al. 1994. PubMed ID 8182131; Chou and Mansfield. 2008. PubMed ID 18449899). This variant is reported in 0.038% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/17-41063408-C-T). Nonsense variants in G6PC1 are expected to be pathogenic. This variant is interpreted as pathogenic.
OMIM RCV000012780 SCV000033020 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 1994-05-01 no assertion criteria provided literature only
GeneReviews RCV000012780 SCV000040455 not provided Glycogen storage disease due to glucose-6-phosphatase deficiency type IA no assertion provided literature only
Natera, Inc. RCV001027894 SCV001190617 pathogenic Glycogen storage disease 2019-05-20 no assertion criteria provided clinical testing
Natera, Inc. RCV000012780 SCV001453363 pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.